| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| GPX4 Antibody | 52455 | 20 µl | 20, 22 kDa | Rabbit |
| NCOA4 (E8H8Z) Rabbit mAb | 66849 | 20 µl | 80 kDa | Rabbit IgG |
| KEAP1 (D6B12) Rabbit mAb | 8047 | 20 µl | 60-64 kDa | Rabbit IgG |
| NRF2 (D1Z9C) XP® Rabbit mAb | 12721 | 20 µl | 97-100 kDa | Rabbit IgG |
| 4F2hc/SLC3A2 (D3F9D) XP® Rabbit mAb | 47213 | 20 µl | 75-120 kDa | Rabbit IgG |
| FTH1 (D1D4) Rabbit mAb | 4393 | 20 µl | 21 kDa | Rabbit IgG |
| xCT/SLC7A11 (D2M7A) Rabbit mAb | 12691 | 20 µl | 35 kDa | Rabbit IgG |
| DMT1/SLC11A2 (D3V8G) Rabbit mAb | 15083 | 20 µl | 55, 70-100 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The Ferroptosis Antibody Sampler Kit provides an economical means of detecting proteins involved in ferroptosis. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Storage
Background
Ferroptosis is an iron-dependent form of regulated cell death associated with an increase in lipid peroxides (reviewed in 1,2). Free divalent iron (Fe2+) can lead to spontaneous lipid peroxidation through a Fenton reaction. Ferroptosis is regulated by signaling pathways that control iron storage and oxidative stress. Iron homeostasis is controlled, in part, by ferritin, an iron storage protein consisting of a complex of heavy (FTH1) and light (FTL) chains. Levels of ferritin may be regulated by a selective autophagy process targeting ferritin, termed ferritinophagy. This pathway is mediated by nuclear receptor coactivator 4 (NCOA4), a selective cargo receptor for ferritin (3,4). The divalent metal transporter SLC11A2/DMT1/NRAMP2 regulates iron homeostasis through non-heme absorption in the intestine (5). The glutathione peroxidase pathway has been identified as a key antioxidant defense pathway triggering ferroptosis. The compound RSL3, which directly inhibits GPX4, was identified as an activator of ferroptosis (6). GPX4 converts GSH into oxidized glutathione (GSSH) and reduces cytotoxic lipid peroxides. The glutathione peroxidase pathway is further regulated by System Xc-, an amino acid antiporter consisting of a disulfide-linked heterodimer of SLC7A11/xCT and SLC3A2/4F2hc/CD98, and is inhibited by the ferroptosis inducer erastin (7). Regulation of genes involved in oxidative stress, including GPX4, are largely controlled by the transcription factor NRF2 and serves as a defense against ferroptosis (8). Under normal conditions, expression of NRF2 is inhibited through interaction with KEAP1, part of a ubiquitin E3 ligase complex that leads to NRF2 proteasomal degradation. Oxidative stress leads to conformational changes in KEAP1 that disrupts this interaction, resulting in stabilization of NRF2. This process is further regulated through the autophagy pathway in which the autophagy cargo receptor p62/SQSTM1 can competitively inhibit the KEAP1-NRF2 complex, leading to upregulation of NRF2.
- Cao, J.Y. and Dixon, S.J. (2016) Cell Mol Life Sci 73, 2195-209.
- Xie, Y. et al. (2016) Cell Death Differ 23, 369-79.
- Mancias, J.D. et al. (2014) Nature 509, 105-9.
- Dowdle, W.E. et al. (2014) Nat Cell Biol 16, 1069-79.
- Gunshin, H. et al. (1997) Nature 388, 482-8.
- Yang, W.S. et al. (2014) Cell 156, 317-31.
- Dixon, S.J. et al. (2014) Elife 3, e02523.
- Fan, Z. et al. (2017) Oncogenesis 6, e371.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.